{"id":23138,"date":"2025-01-26T14:12:46","date_gmt":"2025-01-26T06:12:46","guid":{"rendered":"https:\/\/flcube.com\/?p=23138"},"modified":"2025-01-26T14:12:49","modified_gmt":"2025-01-26T06:12:49","slug":"jiangsu-vcare-pharmatech-secures-rmb200-million-in-series-c-financing","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=23138","title":{"rendered":"Jiangsu Vcare PharmaTech Secures RMB200 Million in Series C+ Financing"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Jiangsu Vcare PharmaTech Co., Ltd., a China &#8211; based high &#8211; tech pharmaceutical company, has reportedly secured close to RMB200 million (USD27.6 million) in a Series C + financing round. The funding was led by Galaxy Finance, CMG &#8211; SDIC Capital, Yangtze River Industry Group, and other investors. The proceeds will be used to accelerate the clinical development of innovative drugs, enhance the industrial chain layout of contract research organization (CRO) and contract development and manufacturing organization (CDMO) services, boost independent innovation capabilities, and expand the company&#8217;s presence in the fields of synthetic biology and green chemistry.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Funding and Future Plans<\/strong><br>The Series C + financing round underscores Vcare PharmaTech&#8217;s strategic focus on advancing its pipeline of innovative drugs and strengthening its CRO\/CDMO service offerings. The funds will be allocated towards ramping up clinical development programs, particularly for its lead candidate vicagrel, an oral P2Y12 receptor antagonist currently in Phase III. Additionally, the company plans to invest in expanding its industrial chain layout to enhance efficiency and competitiveness in the CRO\/CDMO sector.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Company Background and Pipeline<\/strong><br>Founded in 2010, Vcare PharmaTech has grown into a prominent group company with two core businesses: the research and development (R&amp;D) of innovative drugs and full &#8211; industry &#8211; chain CRO &amp; CDMO services. The company&#8217;s robust pipeline includes vicagrel, its Phase III &#8211; stage P2Y12 receptor antagonist, as well as five other investigational drugs at various clinical stages. Vcare&#8217;s commitment to innovation and sustainable development is further highlighted by its focus on synthetic biology and green chemistry, which align with global trends in pharmaceutical manufacturing and environmental responsibility.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Vcare PharmaTech Co., Ltd., a China &#8211; based high &#8211; tech pharmaceutical company, has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":23140,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[30,19,20,573],"class_list":["post-23138","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-biotech","tag-cro-cmo-cdmo","tag-finance","tag-vcare-pharmatech"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Jiangsu Vcare PharmaTech Secures RMB200 Million in Series C+ Financing - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Vcare PharmaTech Co., Ltd., a China - based high - tech pharmaceutical company, has reportedly secured close to RMB200 million (USD27.6 million) in a Series C + financing round. The funding was led by Galaxy Finance, CMG - SDIC Capital, Yangtze River Industry Group, and other investors. The proceeds will be used to accelerate the clinical development of innovative drugs, enhance the industrial chain layout of contract research organization (CRO) and contract development and manufacturing organization (CDMO) services, boost independent innovation capabilities, and expand the company&#039;s presence in the fields of synthetic biology and green chemistry.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=23138\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jiangsu Vcare PharmaTech Secures RMB200 Million in Series C+ Financing\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Vcare PharmaTech Co., Ltd., a China - based high - tech pharmaceutical company, has reportedly secured close to RMB200 million (USD27.6 million) in a Series C + financing round. The funding was led by Galaxy Finance, CMG - SDIC Capital, Yangtze River Industry Group, and other investors. The proceeds will be used to accelerate the clinical development of innovative drugs, enhance the industrial chain layout of contract research organization (CRO) and contract development and manufacturing organization (CDMO) services, boost independent innovation capabilities, and expand the company&#039;s presence in the fields of synthetic biology and green chemistry.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=23138\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-26T06:12:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-26T06:12:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2608-png.avif\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23138#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23138\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Jiangsu Vcare PharmaTech Secures RMB200 Million in Series C+ Financing\",\"datePublished\":\"2025-01-26T06:12:46+00:00\",\"dateModified\":\"2025-01-26T06:12:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23138\"},\"wordCount\":286,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23138#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/2608-png.avif\",\"keywords\":[\"Biotech\",\"CRO \\\/ CMO \\\/ CDMO\",\"Finance\",\"Vcare PharmaTech\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=23138#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23138\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=23138\",\"name\":\"Jiangsu Vcare PharmaTech Secures RMB200 Million in Series C+ Financing - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23138#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23138#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/2608-png.avif\",\"datePublished\":\"2025-01-26T06:12:46+00:00\",\"dateModified\":\"2025-01-26T06:12:49+00:00\",\"description\":\"Jiangsu Vcare PharmaTech Co., Ltd., a China - based high - tech pharmaceutical company, has reportedly secured close to RMB200 million (USD27.6 million) in a Series C + financing round. The funding was led by Galaxy Finance, CMG - SDIC Capital, Yangtze River Industry Group, and other investors. The proceeds will be used to accelerate the clinical development of innovative drugs, enhance the industrial chain layout of contract research organization (CRO) and contract development and manufacturing organization (CDMO) services, boost independent innovation capabilities, and expand the company's presence in the fields of synthetic biology and green chemistry.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23138#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=23138\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23138#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/2608-png.avif\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/2608-png.avif\",\"width\":1080,\"height\":608,\"caption\":\"Jiangsu Vcare PharmaTech Secures RMB200 Million in Series C+ Financing\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23138#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jiangsu Vcare PharmaTech Secures RMB200 Million in Series C+ Financing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Jiangsu Vcare PharmaTech Secures RMB200 Million in Series C+ Financing - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Vcare PharmaTech Co., Ltd., a China - based high - tech pharmaceutical company, has reportedly secured close to RMB200 million (USD27.6 million) in a Series C + financing round. The funding was led by Galaxy Finance, CMG - SDIC Capital, Yangtze River Industry Group, and other investors. The proceeds will be used to accelerate the clinical development of innovative drugs, enhance the industrial chain layout of contract research organization (CRO) and contract development and manufacturing organization (CDMO) services, boost independent innovation capabilities, and expand the company's presence in the fields of synthetic biology and green chemistry.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=23138","og_locale":"en_US","og_type":"article","og_title":"Jiangsu Vcare PharmaTech Secures RMB200 Million in Series C+ Financing","og_description":"Jiangsu Vcare PharmaTech Co., Ltd., a China - based high - tech pharmaceutical company, has reportedly secured close to RMB200 million (USD27.6 million) in a Series C + financing round. The funding was led by Galaxy Finance, CMG - SDIC Capital, Yangtze River Industry Group, and other investors. The proceeds will be used to accelerate the clinical development of innovative drugs, enhance the industrial chain layout of contract research organization (CRO) and contract development and manufacturing organization (CDMO) services, boost independent innovation capabilities, and expand the company's presence in the fields of synthetic biology and green chemistry.","og_url":"https:\/\/flcube.com\/?p=23138","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-01-26T06:12:46+00:00","article_modified_time":"2025-01-26T06:12:49+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2608-png.avif","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=23138#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=23138"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Jiangsu Vcare PharmaTech Secures RMB200 Million in Series C+ Financing","datePublished":"2025-01-26T06:12:46+00:00","dateModified":"2025-01-26T06:12:49+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=23138"},"wordCount":286,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=23138#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2608-png.avif","keywords":["Biotech","CRO \/ CMO \/ CDMO","Finance","Vcare PharmaTech"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=23138#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=23138","url":"https:\/\/flcube.com\/?p=23138","name":"Jiangsu Vcare PharmaTech Secures RMB200 Million in Series C+ Financing - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=23138#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=23138#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2608-png.avif","datePublished":"2025-01-26T06:12:46+00:00","dateModified":"2025-01-26T06:12:49+00:00","description":"Jiangsu Vcare PharmaTech Co., Ltd., a China - based high - tech pharmaceutical company, has reportedly secured close to RMB200 million (USD27.6 million) in a Series C + financing round. The funding was led by Galaxy Finance, CMG - SDIC Capital, Yangtze River Industry Group, and other investors. The proceeds will be used to accelerate the clinical development of innovative drugs, enhance the industrial chain layout of contract research organization (CRO) and contract development and manufacturing organization (CDMO) services, boost independent innovation capabilities, and expand the company's presence in the fields of synthetic biology and green chemistry.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=23138#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=23138"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=23138#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2608-png.avif","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2608-png.avif","width":1080,"height":608,"caption":"Jiangsu Vcare PharmaTech Secures RMB200 Million in Series C+ Financing"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=23138#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Jiangsu Vcare PharmaTech Secures RMB200 Million in Series C+ Financing"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2608-png.avif","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23138","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=23138"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23138\/revisions"}],"predecessor-version":[{"id":23141,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23138\/revisions\/23141"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/23140"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=23138"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=23138"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=23138"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}